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Abstract
BACKGROUND—We conducted a trial of prophylactic platelet transfusions to evaluate the effect
of platelet dose on bleeding in patients with hypoproliferative thrombocytopenia.
METHODS—We randomly assigned hospitalized patients undergoing hematopoietic stem-cell
transplantation or chemotherapy for hematologic cancers or solid tumors to receive prophylactic
platelet transfusions at a low dose, a medium dose, or a high dose (1.1×1011, 2.2×1011, or
4.4×1011 platelets per square meter of body-surface area, respectively), when morning platelet counts
were 10,000 per cubic millimeter or lower. Clinical signs of bleeding were assessed daily. The
primary end point was bleeding of grade 2 or higher (as defined on the basis of World Health
Organization criteria).
RESULTS—In the 1272 patients who received at least one platelet transfusion, the primary end
point was observed in 71%, 69%, and 70% of the patients in the low-dose group, the medium-dose
group, and the high-dose group, respectively (differences were not significant). The incidences of
higher grades of bleeding, and other adverse events, were similar among the three groups. The median
number of platelets transfused was significantly lower in the low-dose group (9.25×1011) than in the
medium-dose group (11.25×1011) or the high-dose group (19.63×1011) (P = 0.002 for low vs.
medium, P<0.001 for high vs. low and high vs. medium), but the median number of platelet
transfusions given was significantly higher in the low-dose group (five, vs. three in the medium-dose
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and three in the high-dose group; P<0.001 for low vs. medium and low vs. high). Bleeding occurred
on 25% of the study days on which morning platelet counts were 5000 per cubic millimeter or lower,
as compared with 17% of study days on which platelet counts were 6000 to 80,000 per cubic
millimeter (P<0.001).
CONCLUSIONS—Low doses of platelets administered as a prophylactic transfusion led to a
decreased number of platelets transfused per patient but an increased number of transfusions given.
At doses between 1.1×1011 and 4.4×1011 platelets per square meter, the number of platelets in the
prophylactic transfusion had no effect on the incidence of bleeding. (ClinicalTrials.gov number,
NCT00128713.)
The optimal number of platelets in a prophylactic platelet transfusion is controversial.1,2 A
standard dose for adults is considered to be approximately 3×1011 to 6×1011 platelets.3 Higher
doses than these could potentially result in superior hemostasis,4 but a lower dose might be
equally effective while conserving the platelet supply. Two randomized trials with limited
enrollment — one of 111 patients5 and the other of 119 patients6 — have compared a low dose
of platelets to the standard dose. In both trials, the two doses prevented bleeding to a similar
degree. We conducted a randomized trial of prophylactic platelet transfusions to determine the
effects of the dose of platelets on clinical signs of bleeding, the use of platelet and red-cell
transfusions, changes in the recipient’s post-transfusion platelet count, days to next transfusion,
and adverse events.7
METHODS
A subcommittee of the Transfusion Medicine/Hemostasis Clinical Trials Network
investigators designed the study and wrote the manuscript, which was reviewed by all authors.
Site coordinators gathered the data and submitted the results electronically. (The study
investigators and staff are listed in the Appendix.) The data were analyzed with the use of SAS
software (version 9.2).8 The lead author wrote the first draft of the manuscript and vouches for
the completeness and accuracy of the data. Institutional review boards approved the study.
Adults provided written informed consent; and for children, a parent or legal guardian provided
written informed consent. Children provided assent if required by local site policy. A data and
safety monitoring board reviewed the data twice a year. Stopping boundaries for comparison
of the primary end point between each pair of treatment groups were calculated with the use
of an alpha spending function similar to O’Brien–Fleming boundaries.
ELIGIBILITY CRITERIA
Patients were eligible for the study if they were inpatients of any age undergoing hematopoietic
stem-cell transplantation or chemotherapy for hematologic cancers or solid tumors and it was
expected that they would have platelet counts of 10,000 per cubic millimeter or lower for 5
days or more. Additional criteria were a weight of 10 to 135 kg, prothrombin and partial-
thromboplastin times 1.3 times the upper limit of the normal range or less, a fibrinogen level
of 100 mg per deciliter or more, and no previous platelet transfusions for thrombocytopenia
during the current period of hospitalization.
Exclusion criteria were as follows: bleeding of grade 2 or higher, according to the World Health
Organization (WHO) bleeding scale9 (ranging from grades 1 through 4, with higher grades
indicating worse bleeding; see below and the Supplementary Appendix, available with the full
text of this article at NEJM.org) before or at the time of assessment; performance of bedside
platelet leukoreduction; platelet refractoriness within the past 30 days, according to local
criteria; a panel-reactive HLA antibody level of 20% or more; acute promyelocytic leukemia,
idiopathic or thrombotic thrombocytopenic purpura, or the hemolytic–uremic syndrome;
planned prophylactic transfusion of platelets at platelet counts of more than 10,000 per cubic
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millimeter10; major surgery within the previous 2 weeks; use of drugs intended to affect platelet
number or function; pregnancy; and previous enrollment in this platelet-dose trial (PLADO
trial).
STRATIFICATION AND RANDOMIZATION
Body-surface area was calculated from height and weight.11 Patients were randomly assigned
in a 1:1:1 ratio, by means of computer-generated permuted blocks, to receive platelet
transfusions of one of three doses — 1.1×1011, 2.2×1011, and 4.4×1011 platelets per square
meter per transfusion (low-dose group, medium-dose group, and high-dose group,
respectively) — according to four treatment strata12: allogeneic hematopoietic stem-cell
transplantation, autologous or syngeneic hematopoietic stem-cell transplantation,
chemotherapy for hematologic cancer, or chemotherapy for solid tumor. Treatment-group
assignments were balanced within trial sites with the use of dynamic balancing.12 For typical
adults, the medium dose is similar to a standard adult dose with regard to the number of
platelets.
TRANSFUSIONS
The blood-transfusion service was given each patient’s assigned dose and the allowable range,
±25% of the assigned dose. Site staff were not told the patient’s assigned dose, but differences
in transfusion volume prevented complete blinding. Selection of platelets for transfusion to
achieve the correct “attempted dose” was specified as follows. For apheresis platelets, the
platelet count at the time of collection was used to select a partial unit, a single unit, or multiple
units. For pooled platelet concentrates, the mean platelet count per concentrate, based on
quality-control data, was used to determine the number of platelet concentrates to combine.
For each transfusion, an “at-issue” platelet count was obtained to determine the actual dose
transfused. HLA-selected platelets were transfused completely to avoid product wastage,
regardless of the patient’s assigned dose.
Platelets were transfused prophylactically if the morning count was 10,000 per cubic millimeter
or lower (the “trigger” threshold). The patient’s physician could change the transfusion trigger
threshold or dose if required by clinical indications, with a return to study guidelines as soon
as possible. Local practice determined the indications for red-cell transfusion. Platelets and red
cells were leukoreduced by means of filtration.
CLINICAL ASSESSMENTS
Research staff performed daily assessments of bleeding using physical examinations,
interviews with patients, and chart reviews for bleeding events. They also collected data on all
bleeding described in the WHO criteria,9 except they did not perform urine dipstick or stool
guaiac tests. The bleeding data were used to calculate each patient’s daily bleeding grade. Daily
platelet counts, hematocrit values, and hemoglobin levels were also measured.
The primary end point was bleeding of grade 2 or higher. Grade 2 bleeding was defined as
oropharyngeal bleeding or epistaxis for more than 30 minutes during a 24-hour period, purpura
of more than 1 in. (2.54 cm) in diameter, deep hematoma, joint bleeding, melena, hematochezia,
hematemesis, gross hematuria, abnormal vaginal bleeding consisting of more than spotting,
hemoptysis, blood in bronchopulmonary lavage specimens, visible blood in body-cavity fluid
without symptoms, retinal bleeding without visual impairment, spinal-fluid specimens
containing microscopic amounts of blood, or bleeding for more than 1 hour at invasive sites.
9 (See the Supplementary Appendix for definitions of bleeding grades 0 through 4.) If an
investigator indicated possible death from hemorrhage or if a deceased patient had had grade
3 or 4 bleeding, three nonstudy physicians adjudicated whether bleeding was the cause of death.
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Information was collected on all serious adverse events and on events commonly associated
with transfusion that occurred during transfusion or within 4 hours afterward.
STUDY COMPLETION
The study was considered to be completed at 30 days after the first platelet transfusion, after
a 10-day period without a platelet transfusion, at hospital discharge, at death, or at withdrawal
from the study — whichever occurred first.
STATISTICAL ANALYSIS
The primary end point was bleeding of grade 2 or higher; secondary end points were the highest
grade of bleeding, total number of platelets transfused, and number of platelet transfusions.
Other analyses were exploratory. To account for the three pairwise comparisons among the
three treatment groups, two-sided P values of less than 0.017 were considered to indicate
statistical significance. No other adjustment was made for analyzing multiple outcomes. The
study was designed to have a statistical power of 85% to detect an absolute difference of 12.5%
in the incidence of the primary end point for any pair among the three treatment groups, which
required 450 patients per group.
Unless otherwise specified, all analyses were restricted to data for patients who received at
least one platelet transfusion. Results were analyzed according to the patient’s treatment
assignment, even if platelet transfusions were not received at the assigned dose or were not
administered in accordance with the prophylactic transfusion trigger threshold of 10,000
platelets per cubic millimeter.
Dichotomous end points were compared among the groups with the use of Fisher’s exact test.
The highest grade of bleeding was compared using an exact version of the Kruskall–Wallis
test. The time to next transfusion and time to bleeding were compared among the groups by
means of the log-rank test.13 Dose adherence for each transfusion, trigger-threshold adherence
for each study day, pretransfusion and post-transfusion platelet-counts, platelet increments,
and corrected count increments were compared among the groups with the use of generalized
linear models to account for possible correlations between results within each patient.14,15 (The
platelet increment is defined as the post-transfusion platelet count minus the pretransfusion
count; the corrected count increment has a numerator of the platelet increment [in cubic
millimeters] multiplied by the body-surface area [in square meters] and a denominator of the
total number of platelets transfused divided by 1011.) Other continuous variables were analyzed
with the use of the Wilcoxon rank-sum test. The post hoc subgroup analysis of data regarding
the primary end point, according to randomization stratum, used a logistic-regression model
with an interaction term.
RESULTS
STUDY POPULATION
Between 2004 and 2007, a total of 1351 patients were enrolled at 26 sites. Seventy-nine patients
did not receive a platelet transfusion; however, including these patients in the analyses had a
negligible effect on the results. The baseline characteristics of the study patients were well
balanced among the three treatment groups (Table 1).
ADHERENCE WITH PLATELET DOSE AND TRANSFUSION TRIGGER THRESHOLD
Dose adherence was not required for 210 HLA-selected units of platelets and could not be
reliably determined for an additional 331 volume-reduced units from which plasma was
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removed by centrifugation after collection. Among the 5466 prophylactic platelet transfusions
with neither characteristic, the attempted dose was known for 5384 transfusions in 1162
patients — and there was dose adherence for 86% of these low-dose transfusions, 98% of these
medium-dose transfusions, and 93% of these high-dose transfusions (P<0.001 for low dose vs.
medium dose and medium dose vs. high dose) (Table 2). Among the 1162 patients, all known
attempted doses were in adherence for 79%, 92%, and 86% of patients in the low-dose,
medium-dose, and high-dose groups, respectively (P<0.001 for low dose vs. medium dose, and
P = 0.004 for medium dose vs. high dose).
Platelet doses based on at-issue platelet counts were within the patient’s assigned range for
71%, 80%, and 70% of transfusions in the low-dose group, medium-dose group, and high-dose
group, respectively (P = 0.007 for low dose vs. medium dose, and P<0.001 for medium dose
vs. high dose). This result confirms that the platelet-selection procedure usually resulted in
transfusions of at-issue doses in the assigned range. All known at-issue doses were within the
assigned range for 51%, 63%, and 55% of patients in the low-dose, medium-dose, and high-
dose groups, respectively (P<0.001 for low dose vs. medium dose).
Physicians ordered changes in the platelet dose for clinical reasons for 17% of patients in the
low-dose group, 9% in the medium-dose group, and 7% in the high-dose group (P = 0.003 for
low dose vs. medium dose and P<0.001 for low dose vs. high dose). Overall, only 3% of patients
had a dose change before the onset of bleeding of grade 2 or higher.
The trigger threshold of 10,000 platelets per cubic millimeter was adhered to on 90%, 92%,
and 94% of patient-days in the low-dose group, medium-dose group, and high-dose group,
respectively (P<0.001 for low dose vs. high dose). The trigger was adhered to on all study days
for 53%, 62%, and 61% of patients, respectively (P = 0.01 for low dose vs. medium dose).
Physicians ordered changes in the trigger threshold for clinical reasons for 32%, 26%, and 25%
of patients, respectively, but a total of only 7% of patients had a change in the trigger threshold
before the onset of bleeding of grade 2 or higher.
PRIMARY AND SECONDARY END POINTS
In the 1351 patients who underwent randomization, the percentage with at least one episode
of bleeding of grade 2 or higher was 68% in the low-dose group, 67% in the medium-dose
group, and 69% in the high-dose group, with no significant differences among the groups (P
= 0.83 for low dose vs. medium dose and for low dose vs. high dose; P = 0.66 for medium dose
vs. high dose). Among the 1272 patients who received at least one platelet transfusion, the
percentage of patients in each group with at least one episode of bleeding of grade 2 or higher
was not significantly different (71%, 69% and 70%, respectively) (Table 3).
Overall, the highest bleeding grade observed was no bleeding or bleeding of grade 1 in 31%
of patients, grade 2 in 59%, grade 3 in 8%, and grade 4 in 2%. In each group, the median number
of days of bleeding of grade 2 or higher was 1. The median time from randomization to onset
of bleeding ranged from 7 to 8 days. The median number of red-cell units transfused per patient
was 4. A total of 93% of patients received at least one red-cell transfusion. There were no
significant differences among the three groups for any of these end points.
Bleeding of grade 2 or higher occurred in 79% of recipients of allogeneic hematopoietic stem-
cell transplants, 73% of patients who had hematologic cancers and were undergoing
chemotherapy, and 57% of patients undergoing autologous or syngeneic hematopoietic stem-
cell transplantation (P<0.001 for the comparison of the latter group with each of the first two
groups). However, within each of these treatment categories, the platelet dose had no significant
effect on bleeding.
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The 1272 patients who received at least one transfusion were observed for a total of 24,309
days. Figure 1 shows the percentage of days on which bleeding of grade 2 or higher occurred,
according to the patient’s morning platelet-count category. Bleeding of grade 2 or higher
occurred on 25% of days with morning platelet counts of 5000 per cubic millimeter or lower,
17% of days with morning platelet counts from 6000 to 80,000 per cubic millimeter, 13% of
days with morning platelet counts from 81,000 to 100,000 per cubic millimeter, and 8% of
days with morning platelet counts over 100,000 per cubic millimeter (P<0.001 for platelet
counts of ≤5000 per cubic millimeter vs. counts of 6000 to 80,000; P = 0.001 for platelet counts
of 81,000 to 100,000 per cubic millimeter vs. counts of 6000 to 80,000; and P<0.001 for platelet
counts of >100,000 per cubic millimeter vs. counts of 6000 to 80,000) (Fig. 1).
We could calculate the total number of platelets transfused per patient for 1000 patients. The
median number of platelets transfused was 9.25×1011, 11.25×1011, and 19.63×1011 in the low-
dose, medium-dose, and high-dose groups, respectively (P = 0.002 for low dose vs. medium
dose, P<0.001 for high dose vs. low dose and high dose vs. medium dose) (Table 3). The median
number of platelet transfusions administered was five in the low-dose group as compared with
three in the medium-dose group and three in the high-dose group (P<0.001 for low dose vs.
medium dose and low dose vs. high dose).
RESPONSES TO PLATELET TRANSFUSIONS
The low-dose, medium-dose, and high- dose groups differed significantly in the median post
–transfusion platelet count (22,000, 34,000, and 50,000 per cubic millimeter, respectively), the
median increase in platelet count after transfusion (10,000, 19,000, and 38,000 per cubic
millimeter, respectively), and the median number of days until the next transfusion (1.1, 1.9,
and 2.9, respectively) (P<0.001 for all comparisons for all end points) (Table 2). The median
4-hour corrected count increment was 10,000 in the low-dose group, 10,000 in the medium-
dose group, and 11,000 in the high-dose group, with no significant differences among groups.
ADVERSE EVENTS
There were no significant differences among the three groups in the occurrence of any specific
category of serious adverse events or in the percentage of patients who had one or more serious
adverse events (Table 4). Wheezing during or shortly after transfusion was significantly more
common in the high-dose group than in the medium-dose group. Nine patients in the low-dose
group died, as did four patients in the medium-dose group and seven in the high-dose group;
the number of deaths did not differ significantly among the three groups.
STUDY COMPLETION
Completion of the study occurred at the time of hospital discharge for most patients (71%).
Other causes of study completion were an absence of platelet transfusion for 10 days (in 14%
of patients), the elapsing of 30 days from first platelet transfusion (10%), withdrawal from the
study (4%), and death (2%). The three groups did not differ significantly with regard to reasons
for study completion.
DISCUSSION
This study evaluated the effects of platelet dose on hemostasis and transfusion end points. For
a typical adult, the medium dose was equivalent to the standard dose currently used in clinical
practice.16 The low dose was half the medium dose, and the high dose was twice the medium
dose. There were high rates of adherence for platelet doses and transfusion trigger thresholds.
Physicians changed the dose to a nonstudy dose for patients in the low-dose group more often
than for those in the medium-dose and high-dose groups, but the changes were made primarily
after the onset of bleeding of grade 2 or higher.
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The percentages of patients who received at least one platelet transfusion and had bleeding of
grade 2 or higher — 71%, 69%, and 70% in the low-, medium-, and high-dose groups,
respectively — were not significantly different. The only death from hemorrhagic causes
occurred in the high-dose group (from pulmonary hemorrhage). The highest grade of bleeding,
the number of days of bleeding of grade 2 or higher, the number of days before the occurrence
of bleeding of grade 2 or higher, and the occurrence and number of red-cell transfusions also
did not differ significantly among the three groups. These findings confirm that the dose per
prophylactic platelet transfusion, within the range of doses studied, did not significantly affect
bleeding.
The percentage of patients with bleeding of grade 2 or higher was significantly less among
those undergoing autologous or syngeneic hematopoietic stem-cell transplantation (57%) than
among those with hematologic cancers who were undergoing chemotherapy (73%) or those
undergoing allogeneic hematopoietic stem-cell transplantation (79%), as has been described
previously.17 However, platelet dose had no significant effect on bleeding in any of these
treatment categories.
Patients had a 25% risk of having bleeding of grade 2 or higher on days on which the morning
platelet count was 5000 per cubic millimeter or lower, as compared with a 17% risk on days
with counts from 6000 to 80,000 per cubic millimeter. Previous reports suggest that endothelial
integrity can be maintained with platelet counts of 5000 per cubic millimeter or higher.18,19
Further reductions in the risk of bleeding at platelet counts of 80,000 per cubic millimeter or
higher are postulated to be due to an improved clinical status.
The rates of bleeding seen in our trial are higher than those in several other platelet-transfusion
trials.20–22 The reported incidence of bleeding depends on factors that often differ among
studies, such as assessment method, frequency of assessment, criteria used for bleeding grade,
and population of patients.20 In our study, consistent data collection was achieved with the use
of daily hemostatic assessments performed by research staff who were unaware of the treatment
assignments and who followed detailed instructions. Bleeding grades were ascertained on the
basis of objective criteria, thus reducing bias.
To our knowledge, only two previously reported randomized trials, with limited enrollment,
have evaluated the use of low-dose platelet transfusions as compared with standard-dose
transfusions.5,6 Neither trial showed any significant differences regarding bleeding of any
WHO grades — findings similar to those in our study.
The Strategies for Transfusion of Platelets (SToP) study (NCT00420914)6 was halted because
of grade 4 bleeding in three patients in the low-dose group (1.5×1011 to 3.0×1011 platelets per
transfusion), as compared with none in the standard-dose group (3.0×1011 to 6.0×1011 platelets
per transfusion). A stopping rule of a 5% absolute difference between the two groups in the
incidence of grade 4 bleeding was reached after only 58 and 61 patients were enrolled in the
low-dose group and the standard-dose group, respectively. We did not find a significant
difference in the incidence of grade 4 bleeding in our similar, but much larger, cohort. An
important difference between our study and the StoP study was that we adjusted the dose of
platelets for body-surface area, whereas in the StoP study, the same dose range was used for
all patients in each of the two groups.
In our trial, the total number of platelets transfused — 9.25×1011 for the low dose,
11.25×1011 for the medium dose, and 19.63×1011 for the high dose — was significantly
different among the three groups. However, the median number of transfusions per patient was
significantly greater in the low-dose group (five transfusions) than in the medium-or high-dose
group (three transfusions in each group) (P<0.001 for both comparisons). In the SToP study,
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6 the low-dose group also required significantly more transfusions than the standard-dose
group.
As expected, the median platelet increment after transfusion in the low-dose group (10,000 per
cubic millimeter) was approximately half the median increment in the medium-dose group
(19,000 per cubic millimeter), and the median increment in the high-dose group (38,000 per
cubic millimeter) was approximately twice the increment in the medium-dose group. The
number of days until the next transfusion also differed significantly among the three groups:
1.1 days in the low-dose group, 1.9 in the medium-dose group, and 2.9 in the high-dose group.
These data, data from other, smaller studies, and mathematical models all suggest that larger
doses give higher increments and prolonged intervals until the next transfusion.3,23–27
However, the corrected count increment did not differ significantly among the three groups
(i.e., differences in the increment were explained by differences in the number of platelets
transfused).
In conclusion, when prophylactic transfusions are given after a trigger threshold of 10,000
platelets per cubic millimeter or lower is reached, the platelet dose has no significant effect on
the incidence of bleeding in patients with hypoproliferative thrombocytopenia, probably
because few platelets are needed to maintain hemostasis.18,19 A strategy of low-dose
transfusion significantly reduces the quantity of platelets transfused, which could preserve
these scarce blood components but could also increase the number of platelet transfusions.
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Figure 1. Days with Bleeding of Grade 2 or Higher in All three Treatment Groups, According to
Morning Platelet-Count Categories
The percentage of days on which patients had bleeding of grade 2 or higher is shown, along
with the associated 95% confidence intervals (dashed lines), according to the morning platelet-
count category. Data are based on the 24,309 days during the study period on which patients
had both a morning platelet count and information on bleeding of grade 2 or higher. Each
patient-day was treated as a separate unit of analysis. Analyses were adjusted to take into
account that for each patient, the results on various days may be correlated. The interaction
between treatment group and morning platelet-count category was not significant, indicating
that the effect of the morning platelet-count category did not differ significantly among the
three treatment groups; therefore, the data from all three groups are combined.
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